DexCom Stock-Based Compensation 2010-2025 | DXCM

DexCom stock-based compensation for the twelve months ending March 31, 2025 was $0.415B, a 9.72% increase year-over-year.

  • DexCom annual stock-based compensation for 2024 was $0.17B, a 13% increase from 2023.
  • DexCom annual stock-based compensation for 2023 was $0.151B, a 19.21% increase from 2022.
  • DexCom annual stock-based compensation for 2022 was $0.127B, a 11.55% increase from 2021.

DexCom Stock-Based Compensation 2010-2025 | DXCM

  • DexCom annual stock-based compensation for 2024 was $0.17B, a 13% increase from 2023.
  • DexCom annual stock-based compensation for 2023 was $0.151B, a 19.21% increase from 2022.
  • DexCom annual stock-based compensation for 2022 was $0.127B, a 11.55% increase from 2021.
Related Stocks
Company NameMarket
Cap
Intuitive Surgical (ISRG)$185.1B
Thermo Fisher Scientific (TMO)$160.6B
Edwards Lifesciences (EW)$45.9B
Alcon (ALC)$43.1B
IDEXX Laboratories (IDXX)$42.7B
IQVIA Holdings (IQV)$27.7B
Mettler-Toledo (MTD)$24.8B
STERIS (STE)$22.2B
Waters (WAT)$18.1B
SONOVA HOLDING (SONVY)$17.2B
Hologic (HOLX)$14.4B
Sysmex ADR (SSMXY)$10.6B
Penumbra (PEN)$9.3B
Masimo (MASI)$8.8B
Globus Medical (GMED)$7.8B
Glaukos (GKOS)$6B
Teleflex (TFX)$5.1B
Integer Holdings (ITGR)$4.2B
TransMedics (TMDX)$4B
PROCEPT BioRobotics (PRCT)$3.2B
LivaNova (LIVN)$2.4B
Nihon Kohden (NHNKY)$2.1B
Veracyte (VCYT)$2.1B
Elekta AB (EKTAY)$1.9B
Alphatec Holdings (ATEC)$1.6B
Artivion (AORT)$1.4B
Paragon 28 (FNA)$1.1B
Pulse Biosciences (PLSE)$1.1B
OPKO Health (OPK)$1.1B
Tandem Diabetes Care (TNDM)$1B